Search

Your search keyword '"Hoepelman, Im"' showing total 142 results

Search Constraints

Start Over You searched for: Author "Hoepelman, Im" Remove constraint Author: "Hoepelman, Im"
142 results on '"Hoepelman, Im"'

Search Results

2. Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach

3. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

5. Cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients

6. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study

7. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

8. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study

9. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

10. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

11. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

12. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

13. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

15. Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach

16. FREE trial: induction therapy with ART (abacavir/lamivudine/lopinavir/r) followed by maintenance regimen with triple NRTI, compared to continued ART

19. Introduction

21. The Concorde trial

23. The calculated genetic barrier for drug resistance mutations in six different non-B subtypes and two CRFs in a large European dataset is largely similar to subtype B

24. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

25. Differences in the frequency of minor substitutions between HIV-1 subtypes and their potential impact on the genetic barrier for resistance to protease inhibitors

26. Differences in the frequency of minor substitutions between HIV-1 subtypes and their potential impact on the genetic barrier for resistance to protease inhibitors

27. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons

28. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes

29. Chronic Q fever: patient and treatment-related factors influencing long-term quality of life.

30. Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in The Netherlands Before and After Transition to Adult Care.

31. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

32. The role of T cells in the development of cardiovascular disease in HIV-infected patients.

33. Bacteremic complications of intravascular catheter tip colonization with Gram-negative micro-organisms in patients without preceding bacteremia.

34. Immunoglobulin treatment in primary antibody deficiency.

35. Isolation rooms for highly infectious diseases: an inventory of capabilities in European countries.

36. Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach.

37. Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.

38. Acute hepatitis C virus infection.

39. [Less ventilator-associated pneumonia after oral decontamination with chlorhexidine; a randomised trial].

40. [An early switch from intravenous to oral antibiotics is equally effective as the standard intravenous therapy in severe community acquired pneumonia].

41. [Infection-induced vascular disease: little evidence according to the Koch's postulates].

42. [Three patients with indinavir-related urolithiasis].

43. [Diagnosis of hepatic fibrosis and cirrhosis].

44. Identification of genotypically diverse Cryptococcus neoformans and Cryptococcus gattii isolates by Luminex xMAP technology.

45. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.

46. Application of guidelines on preoperative antibiotic prophylaxis in León, Nicaragua.

47. Aetiology and resistance patterns of community-acquired pneumonia in León, Nicaragua.

48. Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia.

49. Prevalence of HIV and syphilis in pregnant women in Leon, Nicaragua.

50. Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy.

Catalog

Books, media, physical & digital resources